Varex Imaging Corporation (VREX) SEC Filings & Earnings Calls
EquiReason read 12 Varex Imaging Corporation SEC filings in the last 12 months. Latest: 8-K on 2026-10-22 — Varex Imaging disclosed two stockholder lawsuits and 13 demand letters challenging the merger with Teledyne, alleging disclosure deficiencies in the proxy statement. Company believ.
Source: SEC EDGAR filings · figures as of 2026-07-03 · read by EquiReason
- Market cap
- 775.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 16 Nov, in 23 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
22 Oct 20268-K · 8.01Varex Imaging disclosed two stockholder lawsuits and 13 demand letters challenging the merger with Teledyne, alleging disclosure deficiencies in the proxy statement. Company believes claims are without merit but is making supplemental disclopen
Risks flagged
Merger-related lawsuits and demand letters could delay or increase cost of the Teledyne acquisition.
“Complaints seek to enjoin the Merger; 13 demand letters received.”
10 Aug 20268-K · 2.02Q3 FY2026 revenues $211M (+4% YoY), non-GAAP gross margin 37% (up from 34%), non-GAAP EPS $0.31 vs $0.13; strong industrial growth; tariff refunds boosted gross profit by ~$10M.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2026 | $211M | +4% y/y |
| GAAP gross margin · Q3-2026 | 36.0% | |
| Non-GAAP gross margin · Q3-2026 | 37.0% | |
| GAAP operating margin · Q3-2026 | 11.0% | |
| Non-GAAP operating margin · Q3-2026 | 12.0% | |
| GAAP net income per diluted share · Q3-2026 | $0.37 | |
| Non-GAAP net income per diluted share · Q3-2026 | $0.31 | +138% y/y |
| Cash flow from operations · Q3-2026 | $21M | |
| Medical revenue · Medical · Q3-2026 | $134M | |
| Industrial revenue · Industrial · Q3-2026 | $77M |
Risks flagged
Pending acquisition by Teledyne introduces execution and regulatory risk; earnings call cancelled and no guidance provided.
“In light of the announced transaction with Teledyne Technologies Incorporated, and as is customary during the pendency of such a transaction, Varex has cancelled its earnings conference call ... and will not be providing financial guidance.” · word for word
Tariff exposure remains a risk despite current refunds; future tariff policy changes could impact costs.
“Changes in import/export regulatory regimes, tariffs, trade wars, and national policies, including exemptions thereto.” · word for word
10 Aug 20268-K · 1.01, 5.02, 7.01Teledyne to acquire Varex for $18.90 per share in cash, aggregate value ~$1.1B including equity awards and net debt. Transaction approved by both boards, expected close early 2027.being acquiredopen
Figures in the filing · each found in the filing text
| Merger Consideration per share · point_in_time | $18.90 | |
| Aggregate Transaction Value · point_in_time | $1.10B |
Risks flagged
Regulatory and stockholder approval risk; transaction may not close
“subject to customary closing conditions, including regulatory approvals and Varex's stockholder approval” · word for word
10 Aug 202610-QVarex entered into a definitive merger agreement to be acquired by Teledyne Technologies for cash; completion expected early 2027, subject to approvals.being acquiredopen
Figures in the filing · each found in the filing text
| Revenue from top customer · Medical · Q3-2026 | 15.0% | |
| Revenue from top 10 customers · Q3-2026 | 53.0% | |
| International revenue percentage · Q3-2026 | 71.0% |
Risks flagged
Merger completion risk
“Completion of the Merger, which is currently expected in early calendar year 2027, is subject to the satisfaction or waiver of certain closing conditions... There is no assurance that all of the conditions will be satisfied or waived, or that the Merger will be completed on the proposed terms, within the expected timeframe, or at all.” · word for word
Tariff and trade policy risk
“Tariffs on imported materials have increased our costs and prices and lowered gross margins on some of our products, and retaliatory tariffs have increased our customers’ costs for products exported from the United States” · word for word
Customer concentration risk
“One customer accounted for 15% of our revenue during the three months ended July 3, 2026, all of which was in our Medical segment.” · word for word
Joint venture litigation risk
“Since August 2023, the VEC joint venture partners have been engaged in judicial proceedings in Germany disputing the validity of certain shareholder resolutions seeking to exclude the other party from the joint venture.” · word for word
7 May 202610-QRevenue from customers outside the US 67; Revenue from customers outside the US (six months) 68; Revenue from top ten customers 52open
Figures in the filing · each found in the filing text
| Revenue from customers outside the US · Q2-2026 | 67.0% | |
| Revenue from customers outside the US (six months) · H1-2026 | 68.0% | |
| Revenue from top ten customers · Q2-2026 | 52.0% | |
| Revenue from top ten customers (six months) · H1-2026 | 52.0% | |
| Revenue from one customer · Medical · Q2-2026 | 19.0% | |
| Accounts receivable from one customer · 2026-04-03 | 13.0% |
Risks flagged
Tariff and Trade Policy Risk
“Tariffs on imported materials have increased our costs and prices and lowered gross margins on some of our products, thereby having a direct adverse impact on our business and results of operations.” · word for word
China Export Control Risk
“Total sales of medical X-ray tubes we imported into China represented approximately 11% of our total revenue during the first six months of fiscal year 2026.” · word for word
Customer Concentration Risk
“We had one customer during the three months ended April 3, 2026 that accounted for 19% of our revenue, all of which was in our Medical segment.” · word for word
Supply Chain Disruption Risk
“Material shortages and delays due to inflation, trade restrictions, geopolitical tensions, armed conflicts, and other constraints have caused, and could in the future cause, us to temporarily stop production of certain products or miss opportunities to pursue additional sales of some products.” · word for word
Joint Venture Dispute Risk
“Since August 2023, the partners to the VEC joint venture have been engaged in judicial proceedings in Germany against one another disputing the validity of certain shareholder resolutions seeking to exclude the other party from the joint venture.” · word for word
7 May 20268-K · 2.02Revenue $216M (+1% y/y); Non-GAAP net income per diluted share $0.21 (-32% y/y); Guidance: FY revenue guidance $860M-$880M; non-GAAP EPS $0.80-$1.00earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $216M | +1% y/y |
| Non-GAAP net income per diluted share · Q2-2026 | $0.21 | -32% y/y |
Guidance
FY revenue guidance $860M-$880M; non-GAAP EPS $0.80-$1.00
Guidance implies modest H2 growth but below prior expectations; tariff uncertainty weighs on outlook.
Risks flagged
Tariff uncertainty and no IEEPA tariff refund assumed in guidance create downside risk.
“While the Company has applied for tariff refunds, no International Emergency Economic Powers Act (IEEPA) tariff refund is assumed in guidance.” · word for word
Cash outflows from operations of $2M and declining cash reserves ($88M from $155M) due to debt redemption and working capital.
“Cash outflows from operations of $2 million; Cash, cash equivalents, and marketable securities was $88 million as of the end of the second quarter, compared to $155 million at the end of fiscal year 2025” · word for word
16 Mar 20268-K · 1.01, 1.02, 2.03, 8.01Varex entered a $490M secured credit facility ($350M term loan, $100M revolver, $40M delayed draw term loan) to refinance $368M 7.875% Senior Secured Notes due 2027 and for working capital. Matures March 13, 2031.open
Figures in the filing · each found in the filing text
| aggregate principal amount of term loan facility · Q1-2026 | $350M | |
| aggregate principal amount of revolving credit facility · Q1-2026 | $100M | |
| aggregate principal amount of delayed draw term loan facility · Q1-2026 | $40M | |
| aggregate principal amount of 2027 Notes redeemed · Q1-2026 | $368M |
Risks flagged
Increased leverage from new debt; $350M term loan drawn immediately.
“Borrowers drew down $350,000,000 from the term loan facility on March 13, 2026.” · word for word
10 Feb 20268-K · 2.02Revenue $210M (+5% y/y); Medical Segment Revenue $145M; Industrial Segment Revenue $65M (+17% y/y); Guidance: Q2 FY2026 revenue guidance $210-225M; non-GAAP EPS $0.15-0.25earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $210M | +5% y/y |
| Medical Segment Revenue · Medical · Q1-2026 | $145M | |
| Industrial Segment Revenue · Industrial · Q1-2026 | $65M | +17% y/y |
| Non-GAAP Gross Margin · Q1-2026 | 34.0% | |
| Non-GAAP EPS · Q1-2026 | $0.19 | +90% y/y |
| GAAP EPS · Q1-2026 | $0.05 |
Guidance
Q2 FY2026 revenue guidance $210-225M; non-GAAP EPS $0.15-0.25
Q2 guidance implies continued growth at similar levels; management optimistic about CT and cargo security demand.
Risks flagged
Cash flow pressure: operating cash outflow of $16M due to working capital build, primarily inventory.
“Cash outflow from operations was $16 million in the first quarter of fiscal year 2026.” · word for word
Supply chain and tariff risks: reliance on limited suppliers and exposure to import/export regulations.
“Risks include changes in import/export regulatory regimes, tariffs, trade wars, and supply chain disruptions.”
10 Feb 202610-QVarex reported Q1 FY2026 revenue of $209.6M (+4.9% YoY) and net income of $2.4M, with Medical segment margin contraction offset by Industrial segment growth.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $210M | +5% y/y |
| Medical Revenue · Medical · Q1-2026 | $145M | +0% y/y |
| Industrial Revenue · Industrial · Q1-2026 | $65M | +17% y/y |
| Gross Profit · Q1-2026 | $70M | +2% y/y |
| Medical Gross Margin · Medical · Q1-2026 | 31.8% | |
| Industrial Gross Margin · Industrial · Q1-2026 | 36.7% | |
| Net Income · Q1-2026 | $2M | |
| Operating Cash Flow · Q1-2026 | $-16M | |
| Backlog · Q1-2026 | $264M | |
| Inventory · Q1-2026 | $328M |
Risks flagged
Tariff and trade war exposure
“Changes to tariff policies in 2025 by the United States and other countries, particularly bilateral United States and Chinese tariffs, impacted our results of operations and profitability in fiscal year 2025 and in the first quarter fiscal year 2026.” · word for word
China regulatory investigation risk
“Total sales of medical X-ray tubes we imported into China represented approximately 12% of our total revenue during the first quarter of fiscal year 2026.” · word for word
Customer concentration
“We had one customer during the three months ended January 2, 2026 that accounted for 16% of our revenue... Our ten largest customers as a group accounted for approximately 52% of our revenue.” · word for word
Inventory build risk
“Cash used for inventories was $14.5 million higher in the three months ended January 2, 2026, compared to the three months ended January 3, 2025, primarily due to an increase in quantity of inventory for anticipated future demand.” · word for word
Joint venture litigation
“Since August 2023, the partners to the VEC joint venture have been engaged in judicial proceedings in Germany against one another disputing the validity of certain shareholder resolutions seeking to exclude the other party from the joint venture.” · word for word
29 Dec 2025DEF 14AProxy statement for 2026 annual meeting, detailing executive compensation structure and fiscal 2025 performance.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $845M | +4% y/y |
| GAAP Net Income (Loss) · FY2025 | $-70M | |
| Adjusted EBIT · FY2025 | $75M | |
| Adjusted EBITDA Margin · FY2025 | 14.6% | |
| Cash and Cash Equivalents and Marketable Securities · FY2025 | $155M | |
| Total Debt Outstanding · FY2025 | $370M | |
| Cash Flow from Operations · FY2025 | $42M | |
| China Revenue · China · FY2025 | $128M | +9% y/y |
| Net Leverage · FY2025 | $1.80 | |
| Cargo Inspection Systems Orders · Industrial · FY2025 | $55M |
Risks flagged
Accounting error correction risk
“During the third quarter of 2025 we identified an accounting error related to our deferred tax assets and liabilities and income tax expense calculations in prior periods.” · word for word
Share price decline risk
“Fiscal year 2025 long-term incentive grant values were reduced by 29% versus fiscal year 2024 as a one-time action to ensure program affordability in light of the decline in the Company’s share price.” · word for word
18 Nov 20258-K · 2.02Revenue $229M (+11% y/y); GAAP gross margin 34; Non-GAAP gross margin 34; Guidance: Q1 FY2026 revenue guidance $200M-$215M; non-GAAP EPS $0.05-$0.25.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $229M | +11% y/y |
| GAAP gross margin · Q4-2025 | 34.0% | |
| Non-GAAP gross margin · Q4-2025 | 34.0% | |
| GAAP operating margin · Q4-2025 | 9.0% | |
| Non-GAAP operating margin · Q4-2025 | 10.0% | |
| GAAP net income per diluted share · Q4-2025 | $0.29 | |
| Non-GAAP net income per diluted share · Q4-2025 | $0.37 | |
| Cash flow from operations · Q4-2025 | $8M | |
| Revenue · FY2025 | $845M | +4% y/y |
| Non-GAAP EBITDA · FY2025 | $122M | +37% y/y |
Guidance
Q1 FY2026 revenue guidance $200M-$215M; non-GAAP EPS $0.05-$0.25.
Guidance implies sequential revenue decline from Q4 but year-over-year growth; management tone positive.
Risks flagged
Cash decreased due to debt repayment; potential liquidity risk if operations weaken.
“Cash, cash equivalents, and marketable securities was $155 million as of the end of fiscal year 2025 compared to $213 million at the end of fiscal year 2024. The primary driver... was due to the use of cash to pay down the outstanding principal of our Convertible Notes.” · word for word
18 Nov 202510-KTotal Revenue $845M (+4% y/y); Medical Segment Revenue $593M (+2% y/y); Industrial Segment Revenue $252M (+10% y/y)open
Figures in the filing · each found in the filing text
| Total Revenue · FY2025 | $845M | +4% y/y |
| Medical Segment Revenue · Medical · FY2025 | $593M | +2% y/y |
| Industrial Segment Revenue · Industrial · FY2025 | $252M | +10% y/y |
| Total Gross Margin · FY2025 | 34.4% | |
| Medical Gross Margin · Medical · FY2025 | 33.8% | |
| Industrial Gross Margin · Industrial · FY2025 | 35.9% | |
| Net Loss · FY2025 | $-70M | +45% y/y |
| Operating Cash Flow · FY2025 | $42M | -12% y/y |
| Total Debt · FY2025 | $368M | -17% y/y |
| Goodwill · FY2025 | $198M |
Risks flagged
Goodwill Impairment Risk
“we recorded a $93.9 million goodwill impairment charge to our Medical reporting unit... If the assumptions used in our analysis are not realized, it is possible that a further impairment charge may need to be recorded in the future.” · word for word
Debt Covenant Compliance Risk
“The Credit Agreement providing for our Revolving Credit Facility contains a minimum consolidated fixed charge coverage ratio of 1.25 to 1.00 and a maximum consolidated total net leverage ratio...” · word for word
Tariff and Trade Risk
“downward revisions in our longer-term forecast received during the quarter, which include the impact of tariffs and the MOFCOM Investigations announcements” · word for word
Varex Imaging Corporation — questions
- What did Varex Imaging Corporation file recently?
- 12 SEC filings in the last 12 months. Latest: 8-K on 2026-10-22 — Varex Imaging disclosed two stockholder lawsuits and 13 demand letters challenging the merger with Teledyne, alleging disclosure deficiencies in the proxy statement. Company believes claims are without merit but is making supplemental discl
Every figure on this page comes from Varex Imaging Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.